

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * <u>Farbstein Motti</u> (Last) (First) (Middle) <u>C/O CAN-FITE BIOPHARMA LTD.</u> <u>26 BEN GURION STREET</u> (Street) <u>RAMAT GAN L3</u> <u>5257346</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>03/18/2026</u>	3. Issuer Name and Ticker or Trading Symbol <u>Can-Fite BioPharma Ltd. [CANF]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner ☒ Officer (give title below) Other (specify below) <u>CEO, CFO and COO</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) ☒ Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Options to Purchase Ordinary Shares ⁽¹⁾⁽²⁾	03/28/2017	12/28/2027	Ordinary Shares	83 ⁽²⁾	2,439.02 ⁽³⁾	D	
Options to Purchase Ordinary Shares ⁽¹⁾⁽²⁾	01/07/2019	01/07/2029	Ordinary Shares	50 ⁽²⁾	2,274.99 ⁽⁴⁾	D	
Options to Purchase Ordinary Shares ⁽¹⁾⁽²⁾	08/27/2020	05/27/2030	Ordinary Shares	333 ⁽²⁾	242.64 ⁽⁵⁾	D	
Options to Purchase Ordinary Shares ⁽¹⁾⁽²⁾	04/13/2021	04/13/2031	Ordinary Shares	500 ⁽²⁾	248.56 ⁽⁶⁾	D	
Options to Purchase Ordinary Shares ⁽¹⁾⁽⁷⁾	07/17/2022	07/16/2032	Ordinary Shares	666 ⁽⁷⁾	242.64 ⁽⁷⁾	D	
Options to Purchase Ordinary Shares ⁽¹⁾⁽⁸⁾	08/01/2023	04/30/2033	Ordinary Shares	2,500 ⁽⁸⁾	25.33 ⁽⁸⁾	D	
Options to Purchase Ordinary Shares ⁽¹⁾⁽⁹⁾	08/07/2024	07/03/2034	Ordinary Shares	2,500 ⁽⁹⁾	26.69 ⁽⁹⁾	D	
Options to Purchase Ordinary Shares ⁽¹⁾⁽¹⁰⁾	09/24/2025	04/29/2035	Ordinary Shares	2,500 ⁽¹⁰⁾	17.47 ⁽¹⁰⁾	D	

Explanation of Responses:

- To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Issuer's 2003 Share Option Plan, 2013 Share Option Plan and 2023 Share Option Plan must be registered in the name of a trustee.
- These options are fully vested and exercisable as of the date hereof.
- The exercise price of this option, originally denominated in New Israeli Shekels ("NIS") in the amount of NIS 7,539, is presented in the table in U.S. dollars ("USD") based on the exchange rate reported by the Bank of Israel on March 10, 2026, which was NIS 3.0910 = USD 1.00.
- The exercise price of this option, originally denominated in NIS in the amount of NIS 7,032, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 10, 2026, which was NIS 3.0910 = USD 1.00.
- The exercise price of this option, originally denominated in NIS in the amount of NIS 750, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 10, 2026, which was NIS 3.0910 = USD 1.00.
- The exercise price of this option, originally denominated in NIS in the amount of NIS 768.30, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 10, 2026, which was NIS 3.0910 = USD 1.00.
- The exercise price of this option, originally denominated in NIS in the amount of NIS 750, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein 582 options are vested, and the remaining 84 options vest in two equal quarterly installments beginning 04/17/2026 and ending 07/17/2026 subject to the Reporting Person's continued service to the Issuer as of such vesting date.
- The exercise price of this option, originally denominated in NIS in the amount of NIS 78.3, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein 1,718 options are vested, and the remaining 782 options vest in five equal quarterly installments beginning 04/01/2026 and ending 04/01/2027 subject to the Reporting Person's continued service to the Issuer as of such vesting date.
- The exercise price of this option, originally denominated in NIS in the amount of NIS 82.5, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein 1,093 options are vested, and the remaining 1,407 options vest in nine equal quarterly installments beginning 07/03/2026 and ending 07/03/2028 subject to the Reporting Person's continued service to the Issuer as of such vesting date.
- The exercise price of this option, originally denominated in NIS in the amount of NIS 54, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein 156 options are vested, and the remaining 2344 options vest in fifteen equal quarterly installments beginning 12/30/2025 and ending 06/30/2029 subject to the Reporting Person's continued service to the Issuer as of such vesting date.

/s/ Motti Farbstein

03/18/2026

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.